SI
FULC icon

Sofinnova Investments’s Fulcrum Therapeutics FULC Stock Holding History

Sofinnova Investments’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-28,600
Closed -$193K – 77
2023
Q4 		$193K Buy
+28,600
New +$127K 0.01% 57
2023
Q1 		– Sell
-631,411
Closed -$4.6M – 58
2022
Q4 		$4.6M Sell
631,411
-165,851
-21% -$1.08M 0.27% 37
2022
Q3 		$6.45M Buy
+797,262
New +$5.71M 0.38% 39
2022
Q2 		– Sell
-229,509
Closed -$5.43M – 60
2022
Q1 		$5.43M Sell
229,509
-388,161
-63% -$5.49M 0.41% 45
2021
Q4 		$10.9M Buy
617,670
+566,664
+1,111% +$11.2M 0.64% 40
2021
Q3 		$1.44M Buy
+51,006
New +$966K 0.09% 68

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sofinnova Investments's FULC Position: Q1 2024 in Review

Sofinnova Investments sold out of Fulcrum Therapeutics (FULC) in Q1 2024, closing a stake of 28,600 shares — an estimated $193K sold.

Sofinnova Investments first reported a position in FULC in Q3 2021 and held it in 6 quarters. The position peaked at $10.9M in Q4 2021. 126 funds tracked by Wall St. Rank hold FULC as of Q1 2024.

  • Sofinnova Investments reported no remaining Fulcrum Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Sofinnova Investments sold 28,600 Fulcrum Therapeutics shares in Q1 2024, an estimated $193K.
  • Sofinnova Investments first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 6 quarters.
  • Sofinnova Investments's Fulcrum Therapeutics position peaked at $10.9M in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2024.

Based on Sofinnova Investments's 13F filing for Q1 2024, filed 15 May 2024.